Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 1.00 |
| ▸ | CNR2 | P34972 | 18/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.88 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.88 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.88 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.88 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.88 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.88 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.88 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627689 | 0.94 | CNR1 (0.88) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL1628047 | 0.94 | CNR1 (1.00) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL5249483 | 0.93 | CNR1 (0.87) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL1628214 | 0.92 | CNR1 (1.00) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL1629780 | 0.92 | CNR1 (0.88) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL1629988 | 0.91 | CNR1 (0.84) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL1628944 | 0.91 | CNR1 (0.84) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL5249755 | 0.91 | CNR1 (0.84) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL5249058 | 0.91 | CNR1 (0.86) | CNR1CNR2GABRA1GABRB1GABRA5 | |
| SCHEMBL1628698 | 0.91 | CNR1 (1.00) | CNR1CNR2GABRA1GABRB1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558252-B1 | SUBSTITUTED FURO [2,3-B]PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | claimed |
| US-7091216-B2 | Substituted furo[2,3-b]pyridine derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | claimed |
| US-20050272763-A1 | Substituted furo[2,3-b]pyridine derivatives | MERCK SHARP & DOHME CORP. | 2005-12-08 | — | — | US | claimed |
| EP-2146997-B1 | SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-10-30 | — | — | US | disclosed |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-10-30 | — | — | US | disclosed |
| WO-2008127585-A1 | SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1558252-B1 | SUBSTITUTED FURO [2,3-B]PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1558252-B1 | SUBSTITUTED FURO [2,3-B]PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7091216-B2 | Substituted furo[2,3-b]pyridine derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1558252-A4 | SUBSTITUTED FURO 2,3-B| PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050272763-A1 | Substituted furo[2,3-b]pyridine derivatives | MERCK SHARP & DOHME CORP. | 2005-12-08 | — | — | US | disclosed |
| EP-1558252-A2 | SUBSTITUTED FURO 2,3-B] PYRIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004012671-A2 | SUBSTITUTED FURO [2,3-B] PYRIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885GABRA1 66/4885 |
| US-20050272763-A1 | Substituted furo[2,3-b]pyridine derivatives | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885GABRA1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.